MADRIGAL PHARMACEUTICALS, INC.: diluted earnings per share
Diluted earnings per share for MADRIGAL PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All MADRIGAL PHARMACEUTICALS, INC. financial histories
What this measure means
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -12.85 | USD/shares | 2026-02-19 | 10-K · 0001628280-26-009514 |
| 2024-01-01 | 2024-12-31 | -21.9 | USD/shares | 2026-02-19 | 10-K · 0001628280-26-009514 |
| 2023-01-01 | 2023-12-31 | -19.99 | USD/shares | 2026-02-19 | 10-K · 0001628280-26-009514 |
| 2022-01-01 | 2022-12-31 | -17.23 | USD/shares | 2025-02-26 | 10-K · 0001628280-25-007980 |
| 2021-01-01 | 2021-12-31 | -14.63 | USD/shares | 2024-02-28 | 10-K · 0001628280-24-007376 |
| 2020-01-01 | 2020-12-31 | -13.09 | USD/shares | 2023-03-03 | 10-K/A · 0001193125-23-060052 |
| 2011-01-01 | 2011-12-31 | -1 | USD/shares | 2012-02-22 | 10-K · 0001047469-12-001243 |
| 2010-01-01 | 2010-12-31 | -0.93 | USD/shares | 2012-02-22 | 10-K · 0001047469-12-001243 |
| 2009-01-01 | 2009-12-31 | 2.32 | USD/shares | 2012-02-22 | 10-K · 0001047469-12-001243 |
Related financial histories
- MADRIGAL PHARMACEUTICALS, INC.: total assets
- MADRIGAL PHARMACEUTICALS, INC.: total liabilities
- MADRIGAL PHARMACEUTICALS, INC.: stockholders equity
- MADRIGAL PHARMACEUTICALS, INC.: cash and cash equivalents
- MADRIGAL PHARMACEUTICALS, INC.: net income or loss
- MADRIGAL PHARMACEUTICALS, INC.: operating cash flow
- MADRIGAL PHARMACEUTICALS, INC.: capital expenditure payments
- MADRIGAL PHARMACEUTICALS, INC.: revenue
- MADRIGAL PHARMACEUTICALS, INC.: contract revenue excluding tax
- MADRIGAL PHARMACEUTICALS, INC.: financing cash flow
- MADRIGAL PHARMACEUTICALS, INC.: investing cash flow
- MADRIGAL PHARMACEUTICALS, INC.: retained earnings or deficit
- MADRIGAL PHARMACEUTICALS, INC.: basic weighted-average shares
- MADRIGAL PHARMACEUTICALS, INC.: diluted weighted-average shares
- MADRIGAL PHARMACEUTICALS, INC.: basic earnings per share
- MADRIGAL PHARMACEUTICALS, INC.: net property, plant and equipment
- MADRIGAL PHARMACEUTICALS, INC.: share-based compensation expense
- MADRIGAL PHARMACEUTICALS, INC.: operating income or loss
- MADRIGAL PHARMACEUTICALS, INC.: current assets
- MADRIGAL PHARMACEUTICALS, INC.: interest expense
- MADRIGAL PHARMACEUTICALS, INC.: current liabilities
- MADRIGAL PHARMACEUTICALS, INC.: current accounts payable
- MADRIGAL PHARMACEUTICALS, INC.: net finite-lived intangible assets
- MADRIGAL PHARMACEUTICALS, INC.: net current accounts receivable
- MADRIGAL PHARMACEUTICALS, INC.: operating expenses
- MADRIGAL PHARMACEUTICALS, INC.: net inventory
- MADRIGAL PHARMACEUTICALS, INC.: selling, general and administrative expense
Inspect the source
- Entity
- MADRIGAL PHARMACEUTICALS, INC. / CIK 0001157601
- Captured
- 2026-09-20T07:42:41.125Z
- SEC response SHA-256
0d1b2363eed5fd0a7c9252ccbad177dd16230bd15986785daf99c7a8d23f207e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001157601.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))